William B. Jones, Senior Vice President of Pharmaceutical Development at Corvus Pharmaceuticals, discusses how Lonza’s reputation for quality and its experience with antibodies were the driving forces in his company’s selection of CDMO for its CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center